Arbutus生物制药 ABUS 深 沪
已收盘 11-07 16:00:00 美东时间
4.50
+0.060
+1.35%
华盛通- 最 高4.51
- 今 开4.44
- 成交量 82.36万股
- 最 低 4.34
- 昨 收 4.44
- 总市值 8.64亿
- 52周最高 5.10
- 市盈率 静 --
- 换手率 0.43%
- 52周最低 2.705
- 委 比 -66.58%
- 总股本 1.92亿
- 历史最高 31.48
- 量 比 0.95
- 振 幅 3.83%
- 历史最低 0.821
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多乳腺癌现“年轻化”趋势 早筛早诊早治是关键
（来源：经济参考报） 近日，GE医疗与铿锵玫瑰战友团（乳腺癌公益爱心组织）联合举办了“炽热之爱 与光同尘——玫瑰绽放”公益艺术展，向社会积极传递“早筛、早诊...
10-22 04:00
乳腺癌：从“健康杀手”到“可管可控”的慢性病
转自：中国科学报 “乳腺癌可防、可治、可控，关键在于早筛、早诊、早治。”近日，在GE医疗与铿锵玫瑰战友团（乳腺癌公益爱心组织）联合主办的“炽热之爱 与光同尘—...
10-20 16:08
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Arbutus Biopharma announced that four abstracts, including imdusiran and AB-101 data, were accepted for poster presentations at AASLD 2025. Notably, the AB-101 abstract was selected as a Poster of Distinction. The studies highlight imdusiran's safety, tolerability, and potential to enhance immune responses in chronic hepatitis B patients, while AB-101 showed promising safety and efficacy as a PD-L1 inhibitor. These findings underscore progress to...
10-07 12:00
Arbutus Biopharma’s Patent Ruling in Pfizer Lawsuit
The latest update is out from Arbutus Biopharma ( ($ABUS) ). On September 9, 20...
09-10 21:30
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.
08-11 19:22
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
Assembly Biosciences announced positive interim results from a Phase 1b study of ABI-5366, a long-acting HSV helicase-primase inhibitor, in participants with recurrent genital herpes. The 350 mg weekly oral dose showed 94% reduction in HSV-2 shedding rate, 98% reduction in high viral load shedding rate, and 94% reduction in genital lesion rate compared to placebo, all statistically significant. The drug demonstrated favorable safety and tolerabil...
08-08 12:00
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics granted 14,000 restricted stock units to two new hires under its 2022 Inducement Plan, vesting over four years. The company, focused on immune-mediated dermatology, aims to innovate treatments for skin diseases.
07-03 20:00
Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical
The latest update is out from Arbutus Biopharma ( ($ABUS) ). On June 20, 2025, ...
06-25 19:59
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Arbutus and Qilu Pharmaceutical have mutually terminated their 2021 strategic partnership for imdusiran in Greater China, with Arbutus regaining global rights. Arbutus launched a Scientific Advisory Board with leading experts in chronic hepatitis B to guide its cHBV pipeline evaluation. Imdusiran has achieved functional cure in 8 patients across Phase 2a trials.
06-25 11:30
Arbutus Biopharma Q1 EPS $(0.13) Misses $(0.10) Estimate, Sales $1.76M Miss $1.78M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 30 percent. This is a 30 percent decrease over losses of $(0.10) per share from the
05-14 19:36
